Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR)
Research type
Research Study
Full title
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
IRAS ID
1012983
Contact name
Habib Zalila
Contact email
Sponsor organisation
Incyte Corporation
Eudract number
2024-520107-12
Clinicaltrials.gov Identifier
Research summary
Povorcitinib (also known as INCB054707) is a novel, potent, oral, small-molecule, selective, JAK1 inhibitor under clinical evaluation in various inflammatory disorders. Janus kinase signaling regulates several proinflammatory pathways and has been well recognized as a key driver for many diseases; further, JAK inhibitors have been approved for various conditions, such as rheumatoid arthritis, atopic dermatitis, and alopecia areata.
This rollover study is designed to enroll participants who are tolerating the study drug and receiving clinical benefit from it as part of predetermined, Incyte-sponsored parent clinical trials of povorcitinib. The parent Protocols contain the relevant disease background information and rationale for use of povorcitinib in each respective indication.
The purpose of this study is to continue assessing long-term safety across inflammatory conditions in which povorcitinib is being evaluated. Eligible participants include those who have completed predetermined, Incyte-sponsored, povorcitinib clinical trials and who have obtained clinical benefit during the parent study.
The dose of povorcitinib in this rollover study will be the same dispensed to the participant during the period immediately preceding enrollment. If the dose in the parent study was blinded, participants should start the rollover study at the lowest povorcitinib dose utilized in the parent study for the respective indication.
This study will collect and assess safety information with regard to AEs; disease-specific efficacy and QoL outcomes may also be collected, depending on the indication.REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
25/EM/0269
Date of REC Opinion
14 Jan 2026
REC opinion
Further Information Favourable Opinion